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Background: Extracorporeal membrane oxygenation (ECMO) is now a candidate therapy for children with acute
respiratory failure.
Case presentation: We report our experience of using central ECMO therapy for acute respiratory distress syndrome
followed by seizure in a 15-month-old girl with a severe epileptic disorder. Her respiratory distress was refractory to
standard medical treatment and mechanical ventilatory support. Her condition was complicated by development
of a pneumothorax. The patient was successfully weaned off ECMO and discharged without deterioration of her
neurological status.
Conclusion: The successful outcome in this case resulted from the central ECMO, which enabled “lung rest” and
adequate cerebral blood flow. In skilled ECMO facilities, early implementation of ECMO would give some
advantages to patients such as the one presented here. Given the invasiveness and the ease of the procedure,
introduction of dual-lumen catheters adequately sized for pediatric patients in Japan is required.
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Extracorporeal membrane oxygenation (ECMO) is now a
candidate therapy for patients with acute respiratory
failure [1-4] based on several reports of ECMO treatment
for acute respiratory failure associated with influenza A
H1N1 infection in both adult and pediatric patients
[5-10]. Implementation of ECMO for pediatric respiratory
failure has almost doubled since 2000. Approximately 350
patients have been treated annually over the past 3 years
worldwide, with a 56% survival rate [11]. We report our
experience of using ECMO for acute respiratory distress* Correspondence: ecmoshingo@gmail.com
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unless otherwise stated.syndrome (ARDS) followed by seizure in a 15-month-old
girl with a severe epileptic disorder. Her respiratory
distress was refractory to standard medical treatment
and mechanical ventilatory support and complicated by
development of a pneumothorax. The patient was suc-
cessfully weaned from ECMO and discharged home
without deterioration in her neurological status.Case presentation
A 15-month-old girl (10.1 kg, 80 cm) presented to our
emergency department because of status epilepticus. She
had been diagnosed as having Dravet syndrome [12]
with SCN1A mutation at the age of 10 months and had
received antiepileptic therapy with stiripentol, valproic
acid, and clobazam. Psychomotor retardation had been
detected at the age of 11 months. She had continued to. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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by as-needed rectal diazepam.
She was having a partial seizure on arrival at hospital,
which was aborted with intravenous midazolam. She was
intubated for airway protection and transferred to our
emergency intensive care unit. Sulbactam/ampicillin
(300 mg/kg/day) was administered for suspected aspir-
ation pneumonia. Once her body temperature had been
controlled, she was free of seizures and did not require
increased doses of antiepileptic drugs.
Her respiratory function deteriorated, however, and she
developed ARDS the day after her admission. Her partial
pressure of O2 (PaO2)/fraction of inspired O2 (FIO2) (P/F)
ratio was 207. She was placed on synchronized intermit-
tent mandatory ventilation. The ventilator settings had to
be gradually increased during the next 4 days from 18/5
cmH2O to 20/10 cmH2O with an increase in FIO2 from
0.40 to 0.80. On day 6, the ventilator settings were
changed to high-frequency oscillation ventilation (HFOV)
because her P/F ratio and oxygenation index (OI) had
worsened to 84 and 19, respectively. Having achieved
complete muscle relaxation, the HFOV settings were
adjusted (mean airway pressure 32 cm H2O, FIO2 0.65,
stroke volume 60 mL, frequency 10 Hz), after which the
P/F ratio and OI improved to 196 and 15.2, respectively.
Her respiratory status stabilized on HFOV. However,
on day 8 her oxygenation suddenly deteriorated to a P/F
ratio of 54 and OI of 55 because of development of a
right pneumothorax (a complication of HFOV), which
required urgent placement of a chest tube. Despite a de-
aeration procedure, her pulmonary function deteriorated
to an OI of 78.9. A decision was made to introduce
venovenous ECMO therapy. A 14 Fr return cannula was
successfully inserted percutaneously into the left internal
jugular vein. However, an attempt to place a 17 Fr drainage
cannula into the right internal jugular vein percutaneously
failed because of an error in guidewire handling and forma-
tion of a hematoma on her neck.
In this emergency situation, the therapeutic strategy
was aggressively changed to venoarterial ECMO. With
the help of a cardiac surgeon, a 21 Fr drainage cannula
and 12 Fr return cannula were placed in the right atrium
and ascending aorta, respectively, via mid-sternotomy.
The ECMO flow was initially set at 1 L/min with rota-
tional frequency of the centrifugal pump. After introduc-
tion of 70% O2 via ECMO, her arterial blood gas values
dramatically improved (PaO2 404 mmHg), and the FIO2
from mechanical ventilation was reduced to 30% with a
lower tidal volume and lower airway pressure (positive
end-expiratory pressure 8 cmH2O, inspiration time 1.5–
1.8 seconds, frequency 5/min). Because of continuous
oozing from the thoracotomy site and hematoma forma-
tion in the right thoracic cavity, substantial volumes of
blood were transfused during ECMO management (redblood cell concentrate 3250 mL; fresh frozen plasma 920
mL; platelets 1350 mL). As the patient was already fluid-
overloaded because of her severe hypoxic and inflamma-
tory status prior to introducing ECMO, continuous renal
replacement therapy was introduced after stabilization on
ECMO to control her fluid balance precisely. To reduce
the risk of bleeding, nafamostat mesilate was used as an
anticoagulant, with a targeted activated clotting time of
150–160 s. The ECMO circuit used had a heparin coating.
On day 12 (fourth day of ECMO), mediastinal lavage
and removal of hematoma from the right thoracic cavity
was performed through re-thoracotomy with no complica-
tions. On day 13 (fifth day of ECMO), 600 mg of surfac-
tant was administered mainly into the right upper and
middle lobar branches, with direct bronchoscopic observa-
tion. According to her lung compliance measured by the
ventilator (Evita Infinity V500, Dräger, Lübeck, Germany)
and serial chest X-ray films, there was gradual improve-
ment, especially after the surfactant therapy (Figure 1).
During ECMO support, central venous oxygen saturation
was stable at around 70%.
Stable hemodynamics having been achieved after 7 days
of ECMO support, the patient was successfully weaned
from ECMO on day 15. Continuous renal replacement
therapy was discontinued simultaneously. Tracheal extu-
bation was performed on day 26. She was discharged from
our intensive care unit on day 34 and discharged home on
day 79 without deterioration in her neurological status.
Support from multiple departments facilitated rapid
introduction of central ECMO and stabilization of the pa-
tient, which contributed greatly to successful treatment of
this pediatric patient with ARDS [2]. There may be coun-
terarguments against using central respiratory ECMO, but
it enabled provision of complete “lung rest,” attenuating
ventilator-induced lung injury [13,14], as did aggressive
treatment with the surfactant. Because of the patient’s
abnormal vessel course and small vessel size, which are
associated with Dravet syndrome, there was no ad-
equately sized double-lumen cannula for this patient
that was available in Japan. The use of bilateral jugular
vein cannulation in ECMO has some risk of increasing
the intracranial venous pressure and development of
superior vena cava syndrome. Also, if we had chosen to
cannulate the jugular veins bilaterally in this patient, it
may have caused deterioration in her neurodevelopmental
status. Therefore, we believe that central ECMO was a
reasonable choice for this patient.
We decided to implement ECMO after detecting a
pneumothorax, which is one of the complications of
HFOV. Whether the timing of ECMO introduction was
optimal in this patient is open to debate. Our respiratory
management strategy for pediatric ARDS patients is based
on the OI as follows: With OI ≥20, implement HFOV; with
OI ≥30, implement ECMO. Two large randomized
Figure 1 Lung compliance and chest radiographs. The line graph shows improvement in lung compliance as calculated by the mechanical
ventilator. Lung compliance was temporarily compromised with interventions such as lavage or surfactant administration; however, it
subsequently recovered to adequate levels. Parallel with recovery of lung compliance, the radiolucency of the lung gradually improved. a) Day
11. b) Day 12 before lavage and hematoma removal. c) Day 13 before surfactant administration. d) Day 15.
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protective ventilation were published in 2013: the Oscilla-
tion for Acute Respiratory Distress Syndrome Treated Early
(OSCILLATE) trial [15] and the Oscillation in ARDS
(OSCAR) trial [16]. These trials suggested that, in adults
with early moderate-to-severe ARDS, HFOV conferred no
benefit and may have been harmful [17]. Historically,
HFOV is preferred for lung protective therapy in small chil-
dren. However the pathophysiology of acute respiratory
failure in neonates is known to differ from that of older
infants and children. Thus, HFOV may also be harmful
to children. With sufficient understanding of the charac-
teristics of both HFOV and ECMO, lowering the criteria
for implementation of ECMO might improve patients’
safety and outcomes.
Easier, less invasive implementation of ECMO should
provide great advantages for pediatric patients with severe
ARDS. The current technique in Japan involves imple-
menting venovenous ECMO using bilateral jugular veins
or venoarterial ECMO using an internal jugular vein and a
common carotid artery. The internal diameter of the cath-
eter is crucial to facilitating sufficient drainage of venous
blood [18]. However, the available catheters with suffi-
ciently large diameters (larger than 15 Fr) in Japan may be
too long for pediatric patients. This makes aspects of the
cannulation procedure (e.g., handling of the guidewire)
more difficult, as we experienced in this patient. Recently,
dual-lumen catheters have gained popularity in western
countries for administering pediatric ECMO [19]. Cur-
rently, these devices are unavailable in Japan. However,
given the invasiveness and the ease of the procedure,
introduction of dual-lumen catheters for pediatric patients
is urgently required in our country.ECMO enabled safe administration of surfactant into tar-
geted lung lobar branches with bronchoscopic guidance.
ECMO provides a safe setting for procedures that are risky
during ventilation. Several researchers have reported that
surfactant is effective in patients with ARDS, especially
children [20,21]. Based on our observations of improve-
ment in lung compliance, we believe that surfactant con-
tributed to our patient’s recovery. However, further
research to verify the effect of surfactant in ARDS patients
is needed. It would be desirable to accumulate a series of
pediatric ARDS patients who have been treated with sur-
factant and in whom relevant variables, including lung
compliance, have been measured.
Severe neurological disorders have been thought to
contraindicate the use of ECMO [22]. According to the
most recent Extracorporeal Life Support Organization
guidelines, however, most contraindications are relative.
Hence, the risk of a procedure should be balanced against
its potential benefits [18]. Pneumonia is one of the most
frequent causes of death in epileptic patients, including
those with Dravet syndrome [23-25]. The development of
ECMO has increased the range of means of managing
such patients. However, ECMO remains an expensive
treatment with a high risk of complications. The indica-
tions should be carefully scrutinized, case by case. From
this perspective, the possibility of implementing ECMO
should be considered at an early stage to ensure sufficient
time to discuss its applicability.
Conclusions
We implemented central venoarterial ECMO for respira-
tory failure in a pediatric patient with a severe epileptic
disorder in an emergency situation. Central respiratory
Nosaka et al. BMC Pediatrics  (2015) 15:29 Page 4 of 4ECMO could be a reasonable choice for small pediatric
patients with severe ARDS. With enough understanding
of the characteristics of ECMO, its early implementation
might improve outcomes. Our results suggest that the
introduction of dual-lumen catheters for pediatric patients
to Japan could lead to safer, less invasive implementation
of ECMO.
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